Please enable JavaScript to continue using this application.

Compare $ABOS vs $CHRS | Chartloom

Compare

$ABOS vs $CHRS

Acumen Pharmaceuticals Inc · Coherus Oncology Inc

ABOS

Acumen Pharmaceuticals Inc

CHRS

Coherus Oncology Inc

Compare $ABOS vs $CHRS

Comparing Acumen Pharmaceuticals Inc and Coherus Oncology Inc

ABOSAcumen Pharmaceuticals Inc

CHRSCoherus Oncology Inc

ABOSAcumen Pharmaceuticals Inc

Market cap

$155M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

—

Rev growth (TTM)

—

YTD performance

5.9%

52W performance

13.8%

FCF yield

-59.4%

CHRSCoherus Oncology Inc

Market cap

$165M

P/E (TTM)

—

Forward P/E (NTM)

—

Forward P/S (NTM)

2.04x

Rev growth (TTM)

-64.3%

YTD performance

-21.9%

52W performance

-39.2%

FCF yield

-112.7%

Add ticker

Add up to 1 more ticker to compare

Relative performance

Each ticker starts at 100. 110 means +10% from the start of this window — not a $110 share price.

ABOS

CHRS

Detailed metrics comparison

ABOS

Acumen Pharmaceuticals Inc

CHRS

Coherus Oncology Inc

Market Cap

ABOS$155M

CHRS$165M

Enterprise Value

ABOS$127M

CHRS$134M

Price

ABOS$2.14

CHRS$1.07

P/E Ratio

ABOSN/A

CHRSN/A

P/S Ratio

ABOS102.45x

CHRS3.24x

EV/Sales

ABOS0.00x

CHRS2.63x

EV/EBITDA

ABOS0.00x

CHRS2.57x

P/B Ratio

ABOS2.58x

CHRS2.95x

P/FCF Ratio

ABOSN/A

CHRSN/A

EV/FCF

ABOS-1.38x

CHRS-0.72x

PEG Ratio

ABOSN/A

CHRSN/A

Forward P/E (NTM)

ABOSN/A

CHRSN/A

Forward P/S (NTM)

ABOSN/A

CHRS2.04x

Revenue (TTM)

ABOS$0

CHRS$51M

Revenue Growth (YoY)

ABOSN/A

CHRS-64.3%

Forward Rev Growth

ABOS1135.7%

CHRS67.8%

Gross Margin (TTM)

ABOS0.0%

CHRS68.9%

Operating Margin (TTM)

ABOS0.0%

CHRS0.0%

EBITDA Margin (TTM)

ABOS0.0%

CHRS-288.0%

Net Margin (TTM)

ABOS0.0%

CHRS-259.4%

FCF Margin (TTM)

ABOSN/A

CHRS-365.2%

Net Income (TTM)

ABOS$-105M

CHRS$-132M

FCF (TTM)

ABOS$-92M

CHRS$-186M

EPS (TTM)

ABOS-$1.45

CHRS-$0.85

ROE (TTM)

ABOS-13627.0%

CHRS-18336.0%

ROA (TTM)

ABOS-8164.0%

CHRS-4290.0%

ROIC (TTM)

ABOS-9709.0%

CHRS-10716.0%

Cash

ABOS$59M

CHRS$83M

Debt

ABOS$32M

CHRS$52M

Net Cash/Debt

ABOS$28M

CHRS$31M

Current Ratio (TTM)

ABOS2.47x

CHRS1.77x

Quick Ratio (TTM)

ABOS2.38x

CHRS1.58x

Debt/Equity (TTM)

ABOS0.55x

CHRS0.85x

Debt/Assets (TTM)

ABOS0.0%

CHRS0.0%

Interest Coverage (TTM)

ABOSN/A

CHRSN/A

Net Debt/EBITDA (TTM)

ABOS0.00x

CHRS0.00x

Beta

ABOS0.30

CHRS0.99

52W Performance

ABOS13.8%

CHRS-39.2%

YTD Performance

ABOS5.9%

CHRS-21.9%

% from 52W High

ABOS-40.6%

CHRS-59.1%

% from 52W Low

ABOS42.7%

CHRS9.9%

Asset Turnover (TTM)

ABOS0.00x

CHRS0.17x

FCF Yield (TTM)

ABOS-59.4%

CHRS-112.7%

Earnings Yield (TTM)

ABOS-68.0%

CHRS-80.1%

Dividend Yield (TTM)

ABOSN/A

CHRSN/A

Rule of 40

ABOS0.0

CHRS-429.5

EV/GP/RG

ABOSN/A

CHRS0.05

Ticker research

View ABOS research View CHRS research

Metric	ABOS Acumen Pharmaceuticals Inc	CHRS Coherus Oncology Inc
Market & Valuation
Market Cap	$155M	$165M
Enterprise Value	$127M	$134M
Price	$2.14	$1.07
P/E Ratio	N/A	N/A
P/S Ratio	102.45x	3.24x
EV/Sales	0.00x	2.63x
EV/EBITDA	0.00x	2.57x
P/B Ratio	2.58x	2.95x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.38x	-0.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.04x
Revenue & Growth
Revenue (TTM)	$0	$51M
Revenue Growth (YoY)	N/A	-64.3%
Forward Rev Growth	1135.7%	67.8%
Profitability
Gross Margin (TTM)	0.0%	68.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-288.0%
Net Margin (TTM)	0.0%	-259.4%
FCF Margin (TTM)	N/A	-365.2%
Net Income (TTM)	$-105M	$-132M
FCF (TTM)	$-92M	$-186M
EPS (TTM)	-$1.45	-$0.85
ROE (TTM)	-13627.0%	-18336.0%
ROA (TTM)	-8164.0%	-4290.0%
ROIC (TTM)	-9709.0%	-10716.0%
Financial Health
Cash	$59M	$83M
Debt	$32M	$52M
Net Cash/Debt	$28M	$31M
Current Ratio (TTM)	2.47x	1.77x
Quick Ratio (TTM)	2.38x	1.58x
Debt/Equity (TTM)	0.55x	0.85x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.30	0.99
52W Performance	13.8%	-39.2%
YTD Performance	5.9%	-21.9%
% from 52W High	-40.6%	-59.1%
% from 52W Low	42.7%	9.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.17x
FCF Yield (TTM)	-59.4%	-112.7%
Earnings Yield (TTM)	-68.0%	-80.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-429.5
EV/GP/RG	N/A	0.05
Ticker research	View ABOS research	View CHRS research

Valuation

P/S Ratio

CHRS

3.24x

ABOS

102.45x

EV/FCF

ABOS

-1.38x

CHRS

-0.72x

Growth & revenue

Revenue Growth TTM

CHRS

-64.3%

Forward Revenue Growth

ABOS

1135.7%

CHRS

67.8%

Profitability & performance

Gross Margin

CHRS

68.9%

ABOS

0.0%

ROE

ABOS

-13627.0%

CHRS

-18336.0%

FCF Yield %

ABOS

-59.4%

CHRS

-112.7%

52-Week Performance

ABOS

13.8%

CHRS

-39.2%

Detailed metrics comparison

ABOS

Acumen Pharmaceuticals Inc

CHRS

Coherus Oncology Inc

Market Cap

ABOS$155M

CHRS$165M

Enterprise Value

ABOS$127M

CHRS$134M

Price

ABOS$2.14

CHRS$1.07

P/E Ratio

ABOSN/A

CHRSN/A

P/S Ratio

ABOS102.45x

CHRS3.24x

EV/Sales

ABOS0.00x

CHRS2.63x

EV/EBITDA

ABOS0.00x

CHRS2.57x

P/B Ratio

ABOS2.58x

CHRS2.95x

P/FCF Ratio

ABOSN/A

CHRSN/A

EV/FCF

ABOS-1.38x

CHRS-0.72x

PEG Ratio

ABOSN/A

CHRSN/A

Forward P/E (NTM)

ABOSN/A

CHRSN/A

Forward P/S (NTM)

ABOSN/A

CHRS2.04x

Revenue (TTM)

ABOS$0

CHRS$51M

Revenue Growth (YoY)

ABOSN/A

CHRS-64.3%

Forward Rev Growth

ABOS1135.7%

CHRS67.8%

Gross Margin (TTM)

ABOS0.0%

CHRS68.9%

Operating Margin (TTM)

ABOS0.0%

CHRS0.0%

EBITDA Margin (TTM)

ABOS0.0%

CHRS-288.0%

Net Margin (TTM)

ABOS0.0%

CHRS-259.4%

FCF Margin (TTM)

ABOSN/A

CHRS-365.2%

Net Income (TTM)

ABOS$-105M

CHRS$-132M

FCF (TTM)

ABOS$-92M

CHRS$-186M

EPS (TTM)

ABOS-$1.45

CHRS-$0.85

ROE (TTM)

ABOS-13627.0%

CHRS-18336.0%

ROA (TTM)

ABOS-8164.0%

CHRS-4290.0%

ROIC (TTM)

ABOS-9709.0%

CHRS-10716.0%

Cash

ABOS$59M

CHRS$83M

Debt

ABOS$32M

CHRS$52M

Net Cash/Debt

ABOS$28M

CHRS$31M

Current Ratio (TTM)

ABOS2.47x

CHRS1.77x

Quick Ratio (TTM)

ABOS2.38x

CHRS1.58x

Debt/Equity (TTM)

ABOS0.55x

CHRS0.85x

Debt/Assets (TTM)

ABOS0.0%

CHRS0.0%

Interest Coverage (TTM)

ABOSN/A

CHRSN/A

Net Debt/EBITDA (TTM)

ABOS0.00x

CHRS0.00x

Beta

ABOS0.30

CHRS0.99

52W Performance

ABOS13.8%

CHRS-39.2%

YTD Performance

ABOS5.9%

CHRS-21.9%

% from 52W High

ABOS-40.6%

CHRS-59.1%

% from 52W Low

ABOS42.7%

CHRS9.9%

Asset Turnover (TTM)

ABOS0.00x

CHRS0.17x

FCF Yield (TTM)

ABOS-59.4%

CHRS-112.7%

Earnings Yield (TTM)

ABOS-68.0%

CHRS-80.1%

Dividend Yield (TTM)

ABOSN/A

CHRSN/A

Rule of 40

ABOS0.0

CHRS-429.5

EV/GP/RG

ABOSN/A

CHRS0.05

Ticker research

View ABOS research View CHRS research

Metric	ABOS Acumen Pharmaceuticals Inc	CHRS Coherus Oncology Inc
Market & Valuation
Market Cap	$155M	$165M
Enterprise Value	$127M	$134M
Price	$2.14	$1.07
P/E Ratio	N/A	N/A
P/S Ratio	102.45x	3.24x
EV/Sales	0.00x	2.63x
EV/EBITDA	0.00x	2.57x
P/B Ratio	2.58x	2.95x
P/FCF Ratio	N/A	N/A
EV/FCF	-1.38x	-0.72x
PEG Ratio	N/A	N/A
Forward P/E (NTM)	N/A	N/A
Forward P/S (NTM)	N/A	2.04x
Revenue & Growth
Revenue (TTM)	$0	$51M
Revenue Growth (YoY)	N/A	-64.3%
Forward Rev Growth	1135.7%	67.8%
Profitability
Gross Margin (TTM)	0.0%	68.9%
Operating Margin (TTM)	0.0%	0.0%
EBITDA Margin (TTM)	0.0%	-288.0%
Net Margin (TTM)	0.0%	-259.4%
FCF Margin (TTM)	N/A	-365.2%
Net Income (TTM)	$-105M	$-132M
FCF (TTM)	$-92M	$-186M
EPS (TTM)	-$1.45	-$0.85
ROE (TTM)	-13627.0%	-18336.0%
ROA (TTM)	-8164.0%	-4290.0%
ROIC (TTM)	-9709.0%	-10716.0%
Financial Health
Cash	$59M	$83M
Debt	$32M	$52M
Net Cash/Debt	$28M	$31M
Current Ratio (TTM)	2.47x	1.77x
Quick Ratio (TTM)	2.38x	1.58x
Debt/Equity (TTM)	0.55x	0.85x
Debt/Assets (TTM)	0.0%	0.0%
Interest Coverage (TTM)	N/A	N/A
Net Debt/EBITDA (TTM)	0.00x	0.00x
Performance
Beta	0.30	0.99
52W Performance	13.8%	-39.2%
YTD Performance	5.9%	-21.9%
% from 52W High	-40.6%	-59.1%
% from 52W Low	42.7%	9.9%
Efficiency & Yields
Asset Turnover (TTM)	0.00x	0.17x
FCF Yield (TTM)	-59.4%	-112.7%
Earnings Yield (TTM)	-68.0%	-80.1%
Dividend Yield (TTM)	N/A	N/A
Other
Rule of 40	0.0	-429.5
EV/GP/RG	N/A	0.05
Ticker research	View ABOS research	View CHRS research